Clearance and Crossroads: FDA OKs Papzimeos as Pfizer’s Sickle Cell Bet Falters

Biopharma.com reported sharp contrasts, with a landmark approval for a rare disease therapy alongside a high-profile trial miss, and a series of corporate moves reflecting market access and financing realities.…

Continue Reading Clearance and Crossroads: FDA OKs Papzimeos as Pfizer’s Sickle Cell Bet Falters

Unmasking ATTR-CM: How It’s Detected, Who’s at Risk, and What Treatments Do—and Don’t—Do

Diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) is challenging because its symptoms are vague and overlap with many conditions. Providers typically follow a stepwise approach that combines history-taking, targeted testing, and imaging…

Continue Reading Unmasking ATTR-CM: How It’s Detected, Who’s at Risk, and What Treatments Do—and Don’t—Do
*cancer that cannot be removed with surgery or has spread to other parts of the body. GEJ= gastroesophageal junction (where the esophagus joins the stomach)

Acknowledgment: This story is sponsored by Astellas Pharma US Inc. and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing…

Continue Reading

Novartis’ Ianalumab Shows Promise for Sjögren’s Syndrome and Blood Disorder in New Studies

Novartis has announced encouraging results from two pivotal studies involving its experimental drug, ianalumab, targeting two different autoimmune indications. As reported by BioPharma Dive, the Swiss pharmaceutical company revealed positive data…

Continue Reading Novartis’ Ianalumab Shows Promise for Sjögren’s Syndrome and Blood Disorder in New Studies

Sanofi’s SAR446523 Receives Orphan Drug Designation for Multiple Myeloma, Paving Way for Novel Treatment

Sanofi has announced a significant regulatory milestone for its investigational therapy SAR446523, a monoclonal antibody targeting GPRC5D, after the U.S. Food and Drug Administration (FDA) granted it orphan drug designation…

Continue Reading Sanofi’s SAR446523 Receives Orphan Drug Designation for Multiple Myeloma, Paving Way for Novel Treatment

Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients

Lancet Oncology Recently published reports updating the findings from the phase 3 DREAMM 7 trial involving 494 patients averaging ages 64.5 years with the median follow-up of 39.4 months. Accordingly, patients…

Continue Reading Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients